CardioKinetix Scores $48M For Heart Failure Treatment
Menlo Park-based CardioKinetix said Thursday that it has raised $48M in a Series E financing, for its catheter-based heart failure therapies. The new funding round came from Panorama Capital, along with prior investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors. The most recent funding came in the form of a $23M, second tranche of its Series E. The firm said it will use the financing to further advance its programs. Maria Sainz is President and CEO of CardioKinetix.
posted on Friday, March 1, 2013 (Link to more information)
Related companies:
CARDIOKINETIX
Related stories:
> CardioKinetix Gets $44M
> EBR Systems Raises $50M For Wireless Heart Failure Treatment System
> EBR Systems Gets $35M In Third Round
> ReThink Medical Finds $3M To Prevent Heart Failure Issues
> Relypsa Nabs $70M
silicontap.com Home